- Controls inflammatory response
- NSAID approved for oral administration
- Non-steroidal; no steroidal side effects
- Active up to 36 hours
- Safe: Approved by FDA
There are no known contraindications to this drug when used as directed.
The effect of flunixin meglumine on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of flunixin meglumine.
During field studies with flunixin meglumine, no significant side effects were reported.
STORAGE: Store at 20˚C - 25˚C (68˚F - 77˚F); excursions permitted between 15˚C - 30˚C (between 59˚F - 86˚F)
DOSAGE AND ADMINISTRATION:
It is important to follow your Veterinarian's prescription instructions for your pet
The recommended dose of flunixin meglumine is 0.5 mg per lb of body weight once daily. The Prevail Equine Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs. One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.
The paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger. Treatment may be given initially by intravenous or intramuscular injection of Prevail Injectable Solution, followed by Prevail Equine Paste on Days 2 to 5. Flunixin meglumine treatment should not exceed 5 consecutive days.
Equine Paste Syringes 30 g each (syringe contains flunixin meglumine equivalent to 1500 mg flunixin)